TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9534106
Drug: slow-release verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: slow-release verapamil 240 mg/day
Study: 11910310
Drug: trandolapril 2
Normalized name: trandolapril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: trandolapril 2 mg/day
Study: 9534106
Drug: verapamil 180
Normalized name: verapamil 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 180 mg/day plus trandolapril 2 mg/day
Study: 9534106
Drug: trandolapril 2
Normalized name: trandolapril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: trandolapril 2 mg/day plus verapamil 180 mg/day
Study: 7661587
Drug: Best supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best supportive care plus combination chemotherapy
Study: 2693623
Drug: Triple antibiotic
Normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple antibiotic combination (gentamicin, clindamycin, penicillin G)
Study: 28537195
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg kg-1)
Study: 21441549
Drug: Morphine patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine patient-controlled analgesia (PCA)
Study: 19363377
Drug: Psychosocial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial treatment for MA dependence
Study: 12095667
Drug: Dextromethorphan (DM)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DM) 120, 240, and 480 mg/day
Study: 2530546
Drug: IV ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ceftriaxone 2 g daily for 4 days, followed by IM or IV ceftriaxone 1 g daily for 11 days
Study: 2530546
Drug: IV ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ceftriaxone 2 g every other day for 4 days, followed by oral cefixime 200 mg twice daily for 11 days
Study: 25769319
Drug: Ji‐Tai tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ji‐Tai tablet
Study: 25769319
Drug: Ji‐Tai tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ji‐Tai tablet combined with buprenorphine
Study: 23810466
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel + S-1 (paclitaxel 60 mg/m2 on days 1, 8, and 15; S-1 80-120 mg/d on days 1-14)
Study: 23810466
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel + S-1
Study: 23810466
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel + 5-fluorouracil (paclitaxel 60 mg/m2; 5-fluorouracil 500 mg/m2 on days 1-5; leucovorin 20 mg/m2 on days 1-5)
Study: 23810466
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel + 5-fluorouracil
Study: 20587723
Drug: 2-h hyperinsulinemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-h hyperinsulinemic hypoglycemia (2.9 ± 0.1 mmol/l)
Study: 20587723
Drug: Euglycemia (5.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycemia (5.2 ± 0.1 mmol/l)
Study: 18249205
Drug: 22 mg
Normalized name: urea 0.22 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22 mg PSs per kilogram of body weight with a low‐cholesterol diet (C(‐)S(+))
Study: 18249205
Drug: 22 mg
Normalized name: urea 0.22 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22 mg PSs per kilogram of body weight with a high‐cholesterol diet (C(+)S(+))
Study: 18249205
Drug: 22 mg
Normalized name: urea 0.22 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22 mg PSs per kilogram of body weight (both diets)
Study: 10389720
Drug: Weekly stress
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly stress incontinence
Study: 10389720
Drug: Weekly urge
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly urge incontinence
Study: 1988575
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy (chemotherapy and tamoxifen)
Study: 1988575
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy (tamoxifen and chemotherapy)
Study: 6997516
Drug: Single 2-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 2-g dose of metronidazole
Study: 7039761
Drug: Single 1-g
Normalized name: bacitracin
DrugBank: Bacitracin (DB00626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single 1-g dose of metronidazole
Study: 7039761
Drug: Retreatment with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retreatment with a single 2-g dose of metronidazole after initial failure
Study: 29692183
Drug: Moxibustion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion treatment (Group A) from days 1 to 14
Study: 29692183
Drug: Moxibustion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion treatment (Group B) from days 15 to 28
Study: 23758233
Drug: Inhaled racemic
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled racemic adrenaline
Study: 15622223
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A injection followed by surgical deactivation of migraine trigger sites
Study: 8568113
Drug: Omeprazole treatment
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole treatment (n = 8)
Study: 2187310
Drug: Combination regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination regimen with 0.064% betametason dipropionate ointment (Diprosis) for 1 week before dithranol therapy (B + CSV-therapy)
Study: 2187310
Drug: Conventional dithranol
Normalized name: Zithranol
DrugBank: Anthralin (DB11157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dithranol therapy (CSV-therapy)
Study: 758758
Drug: Intravenous acebutolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acebutolol
Study: 30876438
Drug: Low-intensity arm
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity arm training (same quantity, frequency and treatment time as the intervention group)
Study: 26900895
Drug: 1-session treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-session treatment (OST)
Study: 26900895
Drug: 1-session treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-session treatment (OST) and educational support (EST)
Study: 22241639
Drug: Pentoxifylline (PTF)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTF) 400 mg twice a day, n=46
Study: 22241639
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual therapy), n=45
Study: 15175958
Drug: Protocol treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol treatment (n = 27)
Study: 15175958
Drug: Non-protocol treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-protocol treatment (n = 14)
Study: 15175958
Drug: Cisplatin chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin chemotherapy (cumulative dose >/= 400 mg/m2)
Study: 11182191
Drug: Trimetazidine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (40 mg bolus followed by 60 mg/day intravenously for 48 h)
Study: 9638347
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg testosterone buciclate
Study: 9638347
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg testosterone buciclate
Study: 8074262
Drug: Turbuhaler (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turbuhaler (0.5 mg terbutaline x 2)
Study: 8074262
Drug: CFC inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFC inhaler (0.25 mg terbutaline x 4)
Study: 31027110
Drug: Moderate-intensity continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-intensity continuous aerobic exercise (MICAE) 3 times weekly for 12 weeks
Study: 23779062
Drug: IncobotulinumtoxinA (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: IncobotulinumtoxinA (both doses)
Study: 18849173
Drug: Glimepiride (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (1 mg)/Metformin (500 mg)
Study: 18849173
Drug: Glibenclamide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (5 mg)/Metformin (500 mg)
Study: 11093989
Drug: Dexamethasone 5
Normalized name: dexamethasone 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 5 mg (D5)
Study: 11093989
Drug: Dexamethasone 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 2.5 mg (D2.5)
Study: 11093989
Drug: Dexamethasone 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 1.25 mg (D1.25)
Study: 8684648
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine analgesia
Study: 26932142
Drug: Preoperative duloxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative duloxetine treatment
Study: 23592231
Drug: Computerized cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized cognitive behavioral therapy (cCBT)
Study: 14699463
Drug: Adequate antibiotic
Normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate antibiotic treatment
Study: 14699463
Drug: Inadequate antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inadequate antibiotic treatment
Study: 11156542
Drug: UVA‐1 cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVA‐1 cold light treatment
Study: 11156542
Drug: UVA‐1 cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVA‐1 cold light treatment vs Placebo
Study: 9683005
Drug: Ketamine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.3 mg/kg i.v.
Study: 28569454
Drug: Amoxicillin +
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin + Clavulanic acid (2 g/day for 6 days)
Study: 28569454
Drug: Antibiotic +
Normalized name: Antibiotic + Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic + Probiotic (Bifidobacterium longum + lactoferrin)
Study: 28569454
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic therapy (Control group)
Study: 9349846
Drug: Twice-yearly mebendazole
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-yearly mebendazole (500 mg)
Study: 9349846
Drug: Thrice-yearly mebendazole
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thrice-yearly mebendazole (500 mg)
Study: 6102838
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no beta-blocker therapy)
Study: 3709031
Drug: Cetamolol (46
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetamolol (46 +/- 21 mg/day)
Study: 29393233
Drug: Supplemental oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental oxygen or asthma medications
Study: 25790770
Drug: 4.5-mm diameter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5-mm diameter implant (test)
Study: 25790770
Drug: 3.75-mm diameter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75-mm diameter implant (control)
Study: 24037900
Drug: All IPL
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All IPL doses
Study: 23276521
Drug: Adjuvant 5‐fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant 5‐fluorouracil (5‐FU)‐based chemotherapy
Study: 10566571
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg/d for 12 weeks (n = 194)
Study: 10566571
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg/d for 12 weeks (n = 193)
Study: 10566571
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg/d for 12 weeks
Study: 10566571
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg/d for 12 weeks
Study: 9987507
Drug: Dexamethasone 4
Normalized name: dexamethasone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 4 mg/day
Study: 30701815
Drug: Rectal suppositories
Normalized name: Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal suppositories containing IFN‐α2b (1 million IU) and antioxidants (alpha‐tocopherol acetate and ascorbic acid) twice a day for 5 days
Study: 30701815
Drug: Intranasal gel
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal gel formulation containing IFN‐α2b (36 000 IU/1 g) and antioxidants 3 times a day in addition to rectal suppositories
Study: 30701815
Drug: Umifenovir (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umifenovir (reference drug) at a dose of 200 mg 4 times a day for 5 days
Study: 30701815
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rectal and topical dosage forms of IFN‐α2b with antioxidants
Study: 20505654
Drug: Steroids +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids + Cyclophosphamide
Study: 16126373
Drug: Clotiapine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotiapine (40 mg)
Study: 16126373
Drug: Chlorpromazine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (100 mg)
Study: 14728113
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of SSRIs with aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)
Study: 10997885
Drug: Hydroxyurea (HU)
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (HU) therapy in PV patients
Study: 10997885
Drug: Hydroxyurea (HU)
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (HU) therapy in ET patients
Study: 10997885
Drug: Phlebotomy therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phlebotomy therapy in PV patients
Study: 10997885
Drug: Combined groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined groups of PV and ET without myelosuppressive treatment
Study: 31533799
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care intervention (including cognitive-behavioral therapy, care management, and psychotropic medication consultation)
Study: 22130792
Drug: Prednisone 30
Normalized name: prednisone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 30 mg/d (group A)
Study: 22130792
Drug: Sodium perchlorate
Normalized name: sodium perchlorate
DrugBank: Sodium perchlorate (DB16608)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium perchlorate 500 mg twice daily (group B)
Study: 20639801
Drug: Anatomically shaped
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anatomically shaped permanent expander implant McGhan Style 150
Study: 20639801
Drug: Round permanent
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Round permanent expander implant Siltex Becker 25
Study: 10883415
Drug: Triazolam (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.25 mg) administered orally during the follicular phase
Study: 10883415
Drug: Triazolam (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.25 mg) administered orally during the ovulatory phase
Study: 10883415
Drug: Triazolam (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.25 mg) administered orally during the luteal phase
Study: 10883415
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green (0.5 mg/kg) administered as an i.v. bolus during the follicular phase
Study: 10883415
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green (0.5 mg/kg) administered as an i.v. bolus during the ovulatory phase
Study: 10883415
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green (0.5 mg/kg) administered as an i.v. bolus during the luteal phase
Study: 9187068
Drug: G‐CSF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (10 microg per kilogram of body weight per day subcutaneously)
Study: 1586602
Drug: Continuous low
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous low dose infusion of recombinant interleukin-2 (rIL-2) at doses of 0.18 x 10(6) IU, 0.6 x 10(6) IU, 1.8 x 10(6) IU, 3 x 10(6) IU, 6 x 10(6) IU, and 9 x 10(6) IU per m2 per 24 h.
Study: 1586602
Drug: Continuous low
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous low dose infusion of recombinant interleukin-2 (rIL-2) at a dose of 1.8 x 10(6) IU m-2 24 h-1.
Study: 20074020
Drug: Toremifene (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene (20 mg/d)
Study: 18198271
Drug: Antidepressant use
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant use during follow-up
Study: 12519797
Drug: Systematic reviews
Normalized name: Integrase Inhibitors, antiinfectives for systematic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic reviews of herbal medicines
Study: 10958089
Drug: ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine 0.2% followed by ropivacaine 0.1% + 2 microg x ml(‐1) fentanyl infusion
Study: 10958089
Drug: bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.25% followed by bupivacaine 0.125% + 2 microg x ml(‐1) fentanyl infusion
Study: 1579324
Drug: E2 (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 (75 mg) alone
Study: 1579324
Drug: E2 (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 (75 mg) with testosterone (100 mg)
Study: 26475356
Drug: Q3W group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q3W group (capecitabine 1,000 mg/m² twice daily on days 1-14 and oxaliplatin 130 mg/m² on day 1 every 21 days)
Study: 26475356
Drug: Q2W group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q2W group (capecitabine 2,000 mg/m² twice daily on days 1-7 and oxaliplatin 85 mg/m² on day 1 every 14 days)
Study: 18328059
Drug: 1% pimecrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% pimecrolimus cream applied to the right hemi-face, twice daily for 4 weeks
Study: 18328059
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied to the left hemi-face, twice daily for 4 weeks
Study: 19143948
Drug: Midazolam 0.5
Normalized name: midazolam 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.5 mg x kg(‐1) oral 30 min before surgery (max 15 mg)
Study: 11376505
Drug: Tramadol in
Normalized name: tramadol Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol in continuous infusion (dose 12 mg/h)
Study: 11376505
Drug: Ketorolac in
Normalized name: ketorolac Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac in continuous infusion
Study: 11376505
Drug: Morphine in
Normalized name: morphine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine in repeated boluses
Study: 9391249
Drug: Loxiglumide (LOX)
Normalized name: Dexloxiglumide
DrugBank: Dexloxiglumide (DB04856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide (LOX) infusion (66 mumol/kg/h for 10 min followed by 22 mumol/kg/h)
Study: 9391249
Drug: Loxiglumide (LOX)
Normalized name: Dexloxiglumide
DrugBank: Dexloxiglumide (DB04856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide (LOX) infusion
Study: 8203853
Drug: Ciprofloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (400 mg every 8 h)
Study: 8203853
Drug: Imipenem (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem (1,000 mg every 8 h)
Study: 12885750
Drug: L-DOPS
Normalized name: L-DOPS
DrugBank: Droxidopa (DB06262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-DOPS
Study: 9876215
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day donepezil
Study: 1787894
Drug: Heparan sulfate
Normalized name: heparan sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparan sulfate (200 mg/die, one 100 mg tablet twice a day) for 60 days
Study: 11002380
Drug: 0.3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g/day of n-3 PUFA for 8 weeks
Study: 11002380
Drug: 0.6 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 g/day of n-3 PUFA for 8 weeks
Study: 11002380
Drug: 0.9 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 g/day of n-3 PUFA for 8 weeks
Study: 11002380
Drug: 0 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g/day of n-3 PUFA for 8 weeks (placebo)
Study: 9496777
Drug: Acute attack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute attack drugs (sumatriptan, ergot derivatives, NSAIDs)
Study: 9496777
Drug: Oestrogen supplementation
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen supplementation with percutaneous or transdermal oestradiol (100 microg patches)
Study: 9496777
Drug: Antioestrogen agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioestrogen agents (danazol, tamoxifen)
Study: 22228235
Drug: Human rotavirus
Normalized name: Live attenuated human Rotavirus RIX4414 strain Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human rotavirus vaccine
Study: 2527532
Drug: Cilazapril 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 1.25 mg
Study: 2527532
Drug: Cilazapril intravenous
Normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril intravenous 5 micrograms kg‐1
Study: 2527532
Drug: Cilazapril intravenous
Normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril intravenous 20 micrograms kg‐1
Study: 2527532
Drug: Cilazapril repeated
Normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril repeated administration for 8 days